Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36055304

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Sep
First author
Powles T

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Sep;23(9):1110-1111. doi: 10.1016/S1470-2045(22)00509-5.
    note
    Source null
    related pmid
    36055297
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Nov;23(11):e487. doi: 10.1016/S1470-2045(22)00601-5.
    note
    Source null
    related pmid
    36328016
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Nov;23(11):e488. doi: 10.1016/S1470-2045(22)00602-7.
    note
    Source null
    related pmid
    36328017
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2022 Nov;23(11):e489. doi: 10.1016/S1470-2045(22)00629-5.
    note
    Source null
    related pmid
    36328018
    relationship
    Comment in
  5. citation
    J Urol. 2023 Mar;209(3):631-633. doi: 10.1097/JU.0000000000003098.
    note
    Source null
    related pmid
    36475932
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2023 Jan;24(1):e1-e2. doi: 10.1016/S1470-2045(22)00740-9.
    note
    Source null
    related pmid
    36603921
    relationship
    Comment in
  7. citation
    Lancet Oncol. 2023 Jan;24(1):e10. doi: 10.1016/S1470-2045(22)00759-8.
    note
    Source null
    related pmid
    36603923
    relationship
    Erratum in
  8. citation
    Eur Urol. 2024 Mar;85(3):306. doi: 10.1016/j.eururo.2023.10.019.
    note
    Source null
    related pmid
    37957046
    relationship
    Comment in

Authors and identifiers

  1. name
    Powles T
    type
    Author
  2. name
    Tomczak P
    type
    Author
  3. name
    Park SH
    type
    Author
  4. name
    Venugopal B
    type
    Author
  5. name
    Ferguson T
    type
    Author
  6. name
    Symeonides SN
    type
    Author
  7. name
    Hajek J
    type
    Author
  8. name
    Gurney H
    type
    Author
  9. name
    Chang YH
    type
    Author
  10. name
    Lee JL
    type
    Author
  11. name
    Sarwar N
    type
    Author
  12. name
    Thiery-Vuillemin A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Powles T
    type
    Author
  2. name
    Tomczak P
    type
    Author
  3. name
    Park SH
    type
    Author
  4. name
    Venugopal B
    type
    Author
  5. name
    Ferguson T
    type
    Author
  6. name
    Symeonides SN
    type
    Author
  7. name
    Hajek J
    type
    Author
  8. name
    Gurney H
    type
    Author
  9. name
    Chang YH
    type
    Author
  10. name
    Lee JL
    type
    Author
  11. name
    Sarwar N
    type
    Author
  12. name
    Thiery-Vuillemin A
    type
    Author
bibliography ids
  1. nci-bib-a360dfe481ed9e81fcb3cf26
book metadata
content sha256
e8016c432ac97aefbb803701aa9ceedcaa36c5d6057d29240aa4c97ee0ef1ea8
document type
citation
dois
  1. 10.1016/S1470-2045(22)00487-9
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:36055304
immutable id
pubmed:36055304@e8016c432ac97aefbb803701aa9ceedcaa36c5d6057d29240aa4c97ee0ef1ea8
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
1133-1144
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Sep;23(9):1110-1111. doi: 10.1016/S1470-2045(22)00509-5.
    note
    Source null
    related pmid
    36055297
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Nov;23(11):e487. doi: 10.1016/S1470-2045(22)00601-5.
    note
    Source null
    related pmid
    36328016
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Nov;23(11):e488. doi: 10.1016/S1470-2045(22)00602-7.
    note
    Source null
    related pmid
    36328017
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2022 Nov;23(11):e489. doi: 10.1016/S1470-2045(22)00629-5.
    note
    Source null
    related pmid
    36328018
    relationship
    Comment in
  5. citation
    J Urol. 2023 Mar;209(3):631-633. doi: 10.1097/JU.0000000000003098.
    note
    Source null
    related pmid
    36475932
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2023 Jan;24(1):e1-e2. doi: 10.1016/S1470-2045(22)00740-9.
    note
    Source null
    related pmid
    36603921
    relationship
    Comment in
  7. citation
    Lancet Oncol. 2023 Jan;24(1):e10. doi: 10.1016/S1470-2045(22)00759-8.
    note
    Source null
    related pmid
    36603923
    relationship
    Erratum in
  8. citation
    Eur Urol. 2024 Mar;85(3):306. doi: 10.1016/j.eururo.2023.10.019.
    note
    Source null
    related pmid
    37957046
    relationship
    Comment in
outcomes validated
false
pmid
36055304
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
7b87ef06169e3e997035759ef38e45faa98baf254b3640507e3db0a774883b40
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Sep
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36055304/
title
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice